Intraocular Pressure Response to Medication in a Clinical Setting: The Marshfield Clinic Personalized Medicine Research Project

McCarty, Catherine A.; Mukesh, Bickol N.; Kitchner, Terrie; Hubbard, William C.; Wilke, Russell A.; Burmester, James K.; Patchett, Richard

doi:10.1097/ijg.0b013e31815c5f3f

Cited by 24 publications

(17 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reduction of IOP may prevent or delay visual field loss in patients with glaucoma or ocular hypertension;4,6 thus, monotherapy with IOP-lowering medications is standard-of-care treatment. However, many patients require multiple IOP-lowering therapies to reach their target IOP 15,91. Drug washout during concomitant administration of multiple medications44 and low adherence and persistence with complex glaucoma therapeutic regimens22,24,27 may reduce the effectiveness of multidrug regimens.…”

Section: Resultsmentioning

confidence: 99%

Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus

Nguyen

2014

PPA

View full text Add to dashboard Cite

Glaucoma is one of the leading causes of blindness and is characterized by optic nerve damage that results in visual field loss. Elevated intraocular pressure (IOP) has been associated with glaucoma progression; thus, IOP-lowering medications are the standard of care for glaucoma. Guidelines suggest monotherapy with IOP-lowering agents such as β-blockers (eg, timolol), prostaglandin analogs, carbonic anhydrase inhibitors (eg, brinzolamide), and α2-receptor agonists (eg, brimonidine). However, monotherapy may provide insufficient IOP reduction in some patients, thereby necessitating the use of multiple IOP-lowering medications. Multidrug regimens may be complex, may increase the risk of preservative-related ocular symptoms, and may potentially reduce overall drug exposure as a consequence of drug washout during closely timed sequential administrations; these difficulties may reduce overall drug efficacy and decrease patient persistence and adherence with multidrug treatment regimens. Fixed-combination medications that provide two IOP-lowering therapies within a single solution are available and may overcome some of these challenges. However, all currently available fixed combinations combine timolol with another IOP-lowering agent, indicating that additional fixed-combination alternatives would be beneficial. To meet this demand, a novel fixed combination of brinzolamide 1% and brimonidine 0.2% (BBFC) has recently been developed. In two randomized, double-masked, multinational clinical trials, BBFC had greater IOP-lowering efficacy than brinzolamide or brimonidine monotherapy after 3 months of treatment in patients with open-angle glaucoma or ocular hypertension. In both studies, the overall safety profile of BBFC was consistent with that of brinzolamide and brimonidine. Comparative studies with BBFC versus other IOP-lowering monotherapy and fixed-combination medications are not available, but the IOP reductions observed with BBFC are similar to or greater than those reported in the literature for other glaucoma treatments; thus, BBFC provides an additional fixed-combination therapeutic option for patients who require further efficacious IOP reduction and improved convenience and tolerability versus concomitant administration of two separate medications.

show abstract

Section: Resultsmentioning

confidence: 99%

Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus

Nguyen

2014

PPA

View full text Add to dashboard Cite

show abstract

“…However, as patients with glaucoma have relatively mild subjective symptoms until their condition worsens and the efficacy of ophthalmic solutions is not easily noticeable, both the adherence to and continuity of treatment are reportedly poor [1,2]. The number of glaucoma patients who use two or more anti-glaucoma ophthalmic solutions concurrently is increasing in both Japan [3] and other countries [4]. It has been reported that the use of fewer ophthalmic solutions would decrease the burden on patients and improve adherence to treatment while at the same time reducing adverse effects [5,6].…”

Section: Introductionmentioning

confidence: 97%

Efficacy and safety of switching to travoprost/timolol fixed-combination therapy from latanoprost monotherapy

Kashiwagi

2012

Jpn J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Most patients use antiglaucoma ophthalmic solutions and it is estimated that each patient uses an average of two antiglaucoma ophthalmic solutions. 1 However, studies have revealed that glaucoma patients show poor adherence to antiglaucoma ophthalmic solutions 2 and adherence worsens with an increase in the number of antiglaucoma ophthalmic solutions used. 3 Okeke et al reported that ophthalmologists could not monitor adherence accurately.…”

mentioning

confidence: 99%

Development of Latanoprost-Loaded Biodegradable Nanosheet as a New Drug Delivery System for Glaucoma

Kashiwagi

Ito

Haniuda

et al. 2013

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

Citation: Kashiwagi K, Ito K, Haniuda H, Ohtsubo S, Takeoka S. Development of latanoprost-loaded biodegradable nanosheet as a new drug delivery system for glaucoma. Invest Ophthalmol Vis Sci. 2013;54:5629-5637. DOI:10.1167/iovs.12-9513 PURPOSE. We investigated the IOP reduction and safety of latanoprost-loaded biodegradable nanosheet (LBNS) as a new antiglaucoma drug delivery system (DDS).METHODS. We fabricated a 40 nm thick multilayered biodegradable nanosheet that is composed of chitosan and sodium alginate by means of the layer-by-layer method. Latanoprost isopropyl ester was loaded on the nanosheet to prepare 25, 2.5, and 0.25 lg/ cm 2 LBNSs. A nanosheet without latanoprost isopropyl ester (NS) and 0.005% latanoprost ophthalmic solution were prepared as controls. LBNSs or NS was applied to rat cornea, and IOP was monitored for 9 days. Local adverse effects and eye scratching movement also were investigated. The amount of latanoprost acid in aqueous humor and was measured in rabbits.RESULTS. The 0.25 lg/cm 2 LBNS and 0.005% latanoprost ophthalmic solution showed significant IOP reduction only for 1 day after application, whereas the IOP reduction rates of 2.5 lg/cm 2 LBNS at 1, 2, 4, 7, and 9 days after application were À27.0% 6 14.8%, À22.0% 6 16.7%, À25.8% 6 18.0%, À22.7% 6 20.9%, and À6.6% 6 17.0%, respectively. The 25 lg/cm 2 LBNS reduced IOP in a similar manner. The 25 lg/cm 2 LBNS induced transient hyperemia, whereas the 0.25 and 2.5 lg/cm 2 LBNSs did not exert any local adverse effects. The eye scratching movement test showed that application of 25 lg/cm 2 LBNS did not cause any irritation of the eye. Latanoprost acid was detected in aqueous humor up to 6 days after application of 2.5 lg/cm 2 LBNS.CONCLUSIONS. LBNS may be used as a novel antiglaucoma DDS.

show abstract

Intraocular Pressure Response to Medication in a Clinical Setting: The Marshfield Clinic Personalized Medicine Research Project

Abstract: In this clinic-based setting, we found that treatment of glaucoma has changed over the past 20 years, with ophthalmologists more likely to begin treatment at lower baseline levels of IOP, and prostaglandin analogs the most commonly prescribed and agent to lower IOP.

Cited by 24 publications

References 16 publications

Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus

Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus

Efficacy and safety of switching to travoprost/timolol fixed-combination therapy from latanoprost monotherapy

Development of Latanoprost-Loaded Biodegradable Nanosheet as a New Drug Delivery System for Glaucoma

Contact Info

Product

Resources

About